Why We Sleep: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
Line 56:
=== IV – From Sleeping Pills to Society Transformed ===
👻 '''12 – Things That Go Bump in the Night: Sleep Disorders and Death Caused by No Sleep.''' In 1986, neurologist Elio Lugaresi’s group in Bologna published a New England Journal of Medicine report on a family with fatal familial insomnia, a prion disease marked by selective degeneration of thalamic nuclei and an unstoppable slide from sleeplessness to autonomic failure (mean course about a year). Six years later, a companion NEJM paper tied the syndrome to a PRNP D178N mutation, putting genetics on the map of sleep pathology. The lesson is stark: remove the thalamic gate and the capacity for sleep collapses. Animal work made the danger concrete—at the University of Chicago in 1989, rats kept awake by the disk-over-water method all died or had to be sacrificed within 11–32 days despite eating more, a sign that deprivation itself, not starvation, was lethal. Other disorders show what happens when specific sleep systems fail: in REM sleep behavior disorder, the brainstem’s atonia circuit goes offline and people act out dreams. Follow-up across 24 centers found idiopathic RBD converts to Parkinson’s spectrum disease at about 6.3% per year—roughly three-quarters by 12 years—making it an early alarm for neurodegeneration. Narcolepsy highlights another circuit, with orexin loss destabilizing the sleep–wake switch and triggering sudden REM intrusions. Together, these conditions function like “lesion studies”: each breakdown reveals a job sleep normally does. The core idea is simple: sleep is a biological necessity enforced by dedicated brain machinery, and when that machinery is damaged or chronically overridden, the bill comes due. Mechanistically, thalamic gating, brainstem inhibition, and hypothalamic drive form a system you can’t cheat without cost.
📱 '''13 – iPads, Factory Whistles, and Nightcaps: What’s Stopping You from Sleeping?.''' A two‑week inpatient study at Brigham and Women’s Hospital put people on fixed 22:00–06:00 schedules under dim light (~3 lux) and swapped paper books for LED e‑readers; the light‑emitting screens (spectral peak ~450 nm) suppressed evening melatonin, delayed internal time, lengthened sleep onset, and blunted next‑morning alertness. The mechanism was not subtle: short‑wavelength light hits the melanopsin pathway, telling the suprachiasmatic nucleus that it’s still daytime. The “factory whistles” are modern shift schedules; by 2019 the International Agency for Research on Cancer classified night‑shift work as “probably carcinogenic” (Group 2A), reflecting the systemic impact of chronic circadian disruption. Add the common nightcap: alcohol sedates the cortex but fragments sleep and trims REM later in the night, leaving people awake at 3 a.m. despite “falling asleep fast.” Temperature control matters too; climate‑sealed rooms flatten the normal evening drop in core body temperature that opens the gate to sleep. Caffeine pushes the other lever by blocking adenosine, erasing sleep pressure and lingering into the night thanks to its multi‑hour half‑life. Environmental noise and irregular bedtimes compound the problem, creating a mismatch between the body clock and the social clock. The idea is to remove friction: light, timing, substances, and temperature are inputs you can dial. Mechanistically, circadian (SCN‑driven) timing and homeostatic (adenosine‑driven) pressure are the two dials; align both and sleep arrives on time.
💊 '''14 – Hurting and Helping Your Sleep: Pills vs. Therapy.''' A randomized controlled trial in JAMA (Norway, 2004–2005) assigned 46 older adults with chronic insomnia to six weeks of CBT‑I, nightly zopiclone 7.5 mg, or placebo; at six months, the CBT‑I group’s polysomnographic sleep efficiency rose from 81.4% to 90.1% and slow‑wave sleep increased, while the medication group showed no durable advantage over placebo. In 2016 the American College of Physicians made CBT‑I first‑line treatment for chronic insomnia, reflecting results across delivery modes (individual, group, digital). A 2015 Annals meta‑analysis pooling 20 RCTs (1,162 participants) quantified what patients feel: ~19 minutes faster sleep onset, ~26 minutes less wake after sleep onset, and nearly 10 percentage points higher sleep efficiency, with benefits persisting beyond treatment. Drug therapy can help in select cases, but the U.S. FDA added a 2019 boxed warning to zolpidem, zaleplon, and eszopiclone for rare yet serious “complex sleep behaviors” (sleep‑driving, cooking, injury, even death). Pharmacologically induced sleep also changes architecture—often shifting spindles and REM proportions—so sedation may not restore the same next‑day cognition as natural sleep. CBT‑I, by contrast, uses stimulus control and sleep restriction to rebuild a tight association between bed and sleep and to amplify adenosine pressure before lights‑out. The practical takeaway is to start with behaviors and only layer medications briefly, with clear goals and exit plans. Mechanistically, CBT‑I reshapes learned associations and recalibrates the sleep‑wake switch; pills can open the door, but lasting change comes from how you schedule, cue, and value sleep.
🏛️ '''15 – Sleep and Society: What Medicine and Education Are Doing Wrong; What Google and NASA Are Doing Right.'''
| |||